Neodyne Biosciences Launches First-Ever National Advertising Campaign For embrace® Active Scar Defense

Wednesday, April 12, 2017 General News
Email Print This Page Comment
Font : A-A+

Direct-to-consumer campaign designed to educate about unique science behind only FDA cleared scar therapy clinically proven to prevent scar formation

MENLO PARK, Calif., April 12, 2017 /PRNewswire/ -- Neodyne Biosciences, Inc. today announced the launch of its

first national advertising campaign for embrace® Active Scar Defense, the only FDA cleared scar therapy system designed to relieve tension surrounding incisions, general cuts and lacerations to prevent scarring before it begins. The campaign is designed to raise awareness of and drive interest in embrace® Active Scar Defense for individuals following a surgical procedure or injury.

The direct-to-consumer campaign will include national television commercials, digital advertising, public relations and social media marketing. Neodyne has plans to expand the availability of embrace® Active Scar Defense to top drugstore retailers across the U.S. in late 2017.

"Post-surgical scarring can have dramatic and lasting effects on an individual from a physical and emotional perspective," said Kelley Lipman, President & Chief Commercial Officer at Neodyne Biosciences. "We are excited to build broader awareness among the millions of consumers who may not be familiar with the unique science behind embrace® Active Scar Defense that can actually prevent the appearance and texture of scars before they start."

Embrace® Active Scar Defense works by gently holding both sides of a closed incision together, relieving skin tension, stabilizing and securing the incision from everyday movement and softening and hydrating the skin to protect from raised and pigmented scars. Unlike creams, gels and other treatments that require daily application, the embrace® Active Scar Defense dressing lasts for 10 days and can be worn during exercise or showering. Treatment with embrace® Active Scar Defense has been shown to result in thinner, smoother and lighter scars.

"This integrated campaign is designed to drive awareness and educate millions of consumers about a game changing technology that is proven to prevent scars. We will extend the reach and motivate consumers to learn more about embrace® through digital marketing, social media and CRM, ultimately converting leads and creating advocacy for the brand," said Jim Venable, Director of Marketing & Commercial Operations. "We are excited to embark on this new initiative and look forward to obtaining meaningful insights that will help drive additional interest as we expand the availability of embrace® to retail later this year."

To learn more about embrace® Active Scar Defense, visit www.embracescartherapy.com or call 1-855-722-7879.

About Neodyne Biosciences, Inc.

Neodyne Biosciences (www.neodynebio.com) is an evidence based company developing and commercializing innovative tissue repair devices to minimize scar formation, restoring both function and aesthetic appearance. The company is developing stress-shielding devices capable of controlling the mechanical wound environment to ameliorate post-surgical scarring. Although the etiology remains unclear, mechanical forces such as surrounding skin tension and body movement have been demonstrated to increase fibrosis and scar formation. It is estimated that approximately 80 million major surgical procedures are performed in the United States each year and 230 million performed worldwide. Patient frustration with post-surgical scarring spans a variety of procedures with many seeking means of prevention and treatment.

Neodyne Media Contact:Adrienne Kemp, GOLD PR for Neodyneakemp@goldpr.com | 949-922-0801

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neodyne-biosciences-launches-first-ever-national-advertising-campaign-for-embrace-active-scar-defense-300438521.html

SOURCE Neodyne Biosciences, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook